Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04903717 · ClinicalTrials.gov registry record · NA
Pragmatic Trial Of Alerts for Use of Mineralocorticoid Receptor Antagonists
A NA study, sponsored by Yale University.
- Completed
- Registry status
- NA
- Development phase
- 1,210
- Enrollment target
NCT04903717: Completed NA study, sponsored by Yale University.
NCT04903717 is a NA study that has completed, run by Yale University. The registered enrollment target is 1,210 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (14% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04903717, a NA study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- NA
- Development phase
- 1,210 participants
- Enrollment target
Study Summary
The primary objective of this study is to determine if a best practice alert (BPA) system that prompts providers to consider the addition of a mineralocorticoid receptor antagonist (MRA) in eligible patients with heart failure with reduced ejection fraction (HFrEF) will result in increased prescription of this guideline-recommended therapy. The system will also inform providers about FDA-approved potassium binders for the treatment of hyperkalemia if elevated potassium is a barrier for MRA use and will provide educational information on the evidence for MRA therapy in these patients.
Primary Outcome
Proportion of patients with an active prescription for an MRA, defined as a prescription present in the electronic health record for any drug in the MRA class that is active (not expired) and has remaining doses left at 6 months after the date of randomization.
Interventions
- BEHAVIORAL Best Practice Alert
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,210 participants |
| Start Date | 2021-11-03 |
| Est. Completion | 2024-02-06 |
| Phase | NA |
What the finished NCT04903717 record still lists
NCT04903717 is an interventional study that assigns participants to a tested intervention. Its 1,210 participants enrollment target places it among the larger protocols in the corpus, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (14% lower).
The record links to 0 conditions, and to 1 intervention - of which Best Practice Alert is the first listed.
NCT04903717 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04903717 about?
NCT04903717 is a clinical study titled "Pragmatic Trial Of Alerts for Use of Mineralocorticoid Receptor Antagonists". The primary objective of this study is to determine if a best practice alert (BPA) system that prompts providers to consider the addition of a mineralocorticoid receptor antagonist (MRA) in eligible patients with heart failure with reduced ejection fraction (HFrEF) will result in increased prescript...
What is the current status of trial NCT04903717?
This trial is currently completed. It is a NA study. The enrollment target is 1,210 participants. The study started on 2021-11-03. Estimated completion is 2024-02-06.
What interventions are being tested in trial NCT04903717?
The interventions under investigation include: Best Practice Alert (BEHAVIORAL).
Who is sponsoring clinical trial NCT04903717?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04903717's enrollment target sits among peer trials
1,210 83rd of 2000 higher than 1,918 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04267848 · 1,210 participants · Phase 3
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- NCT05946213 · 1,209 participants · Phase 3
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
- NCT06535854 · 1,205 participants · NA
Prevail Global Study
- NCT07223593 · 1,205 participants · Phase 3
Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI